Form 4/A for VERA Vera Therapeutics, Inc.
Accepted 2026-08-12 18:42:35 ET · period of report 2026-07-07 · accession 0001859453-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DAT | 2026-08-12 18:42 | 2026-07-07 | VERA | Fordyce Marshall | Pres AND CEO, Dir | M - OptEx | $2.90 | +46.2K | 281.5K | +20% | +$134.0K |
| DMAT | 2026-08-12 18:42 | 2026-07-07 | VERA | Fordyce Marshall | Pres AND CEO, Dir | S - Sale+OE | $42.30 | -46.2K | 235.2K | -16% | -$1.96M |
| DAT | 2026-08-12 18:42 | 2026-07-07 | VERA | Fordyce Marshall | Pres AND CEO, Dir | M - OptEx | $0.00 | -46.2K | 525.8K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-07-07 | M | A | 46,250 | $2.90 | 281,494 | D | — | — | (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
| 2 | Common | Class A Common Stock | 2026-07-07 | S | D | 1,000 | $40.78 | 280,494 | D | — | — | (F2) The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F3) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
| 3 | Common | Class A Common Stock | 2026-07-07 | S | D | 32,550 | $42.07 | 247,944 | D | — | — | (F2) The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F4) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
| 4 | Common | Class A Common Stock | 2026-07-07 | S | D | 10,500 | $42.86 | 237,444 | D | — | — | (F2) The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F5) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
| 5 | Common | Class A Common Stock | 2026-07-07 | S | D | 2,200 | $43.59 | 235,244 | D | — | — | (F2) The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F6) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-07-07 | M | D | 46,250 | $0.00 | 525,801 | D | $2.90 · — to 2030-12-15 | 46,250 Class A Common Stock | (F1) This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". (F7) 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |